肾小球疾病的管理和治疗（第 2 部分）：来自肾脏病：改善全球预后（KDIGO）争议会议的结论。

Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

机构信息

Division of Nephrology, The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA.

Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA.

出版信息

Kidney Int. 2019 Feb;95(2):281-295. doi: 10.1016/j.kint.2018.11.008.

DOI:10.1016/j.kint.2018.11.008

PMID:30665569

Abstract

In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative brought a diverse panel of experts in glomerular diseases together to discuss the 2012 KDIGO glomerulonephritis guideline in the context of new developments and insights that had occurred over the years since its publication. During this KDIGO Controversies Conference on Glomerular Diseases, the group examined data on disease pathogenesis, biomarkers, and treatments to identify areas of consensus and areas of controversy. This report summarizes the discussions on primary podocytopathies, lupus nephritis, anti-neutrophil cytoplasmic antibody-associated nephritis, complement-mediated kidney diseases, and monoclonal gammopathies of renal significance.

摘要

2017 年 11 月，肾脏病：改善全球预后（KDIGO）倡议召集了肾小球疾病领域的多位专家，就 2012 年 KDIGO 肾小球肾炎指南进行了讨论，重点是该指南发布以来多年来出现的新进展和新认识。在这次 KDIGO 肾小球疾病争议会议上，专家组对疾病发病机制、生物标志物和治疗方法的数据进行了研究，以确定共识领域和争议领域。本报告总结了原发性足细胞病、狼疮肾炎、抗中性粒细胞胞质抗体相关性肾炎、补体介导的肾脏疾病和肾相关单克隆免疫球蛋白血症的讨论。